Herpes Zoster Wound Pain When Moderate Opioid Therapy Has Not Achieved Adequate Relief
This protocol covers herpes zoster-associated nociceptive pain (wound pain) in patients who have already received a prior analgesic step and whose pain remains above a tolerable level. It outlines the structured approach for this escalation scenario.
Clinical scenario
Herpes zoster-associated nociceptive pain (wound pain) — pain arising directly from the herpetic lesions, requiring stepwise analgesic management guided by pain intensity assessment on a validated scale.
Why this protocol applies
The previous analgesic line — a combination of non-opioid analgesics and mild opioids (tramadol, or tilidine + naloxone) — did not reduce pain to a level the patient can tolerate on a validated pain intensity scale (VAS or NRS, 0–10). This protocol defines the next escalation step.
Next-line approach (partial overview)
The protocol addresses severe pain intensity and employs a combination analgesic strategy, in keeping with the WHO analgesic ladder. It involves both non-opioid and stronger opioid components. The specific agents, their selection rationale, and the complete regimen are available in the full structured protocol.
Treatment goal: Pain reduction to a level the patient can tolerate, measured on a validated pain intensity scale (VAS or NRS, 0–10).
References
DOI: 10.1111/ddg.14013
Analgesic treatment of nociceptive pain based on the WHO's pain relief ladder is recommended (Figure 2).
The treatment goal with respect to herpes zoster-associated pain should be optimal pain relief or at least pain reduction down to a level tolerable for the patient.
View source ↗